ORGANIZATION

The final goal of geneTIGA consortium is to create a T cell therapy against IgA-associated diseases using genome editing which will serve as a blueprint to expand the potential of cell-based gene therapies to chronic immune diseases with high prevalence and lower mortality rates. To achieve this, the project is organized into five WPs on R&D, and one WP each for on management (WP1) and Communication, Dissemination and Exploitation and interaction with existing initiatives (WP7).